Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Twinbeech Capital LP lowered its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 54.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,776 shares of the company's stock after selling 35,683 shares during the period. Twinbeech Capital LP's holdings in Nurix Therapeutics were worth $561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of NRIX. JPMorgan Chase & Co. grew its stake in Nurix Therapeutics by 85.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after buying an additional 31,352 shares during the last quarter. Jump Financial LLC purchased a new position in Nurix Therapeutics during the 4th quarter worth approximately $1,406,000. Barclays PLC grew its stake in Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Nurix Therapeutics by 9.3% in the 4th quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock valued at $17,711,000 after purchasing an additional 79,684 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NRIX. Wells Fargo & Company lowered their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. decreased their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partners assumed coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Trading Up 3.9%

NASDAQ:NRIX traded up $0.38 on Wednesday, hitting $10.15. The company's stock had a trading volume of 94,705 shares, compared to its average volume of 870,200. The stock has a fifty day moving average of $10.51 and a two-hundred day moving average of $16.08. The firm has a market capitalization of $773.80 million, a P/E ratio of -3.51 and a beta of 2.23. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the business posted ($0.76) earnings per share. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares of the company's stock, valued at $707,434. The trade was a 5.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $382,092.92. The trade was a 15.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,838 shares of company stock valued at $221,500 in the last three months. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.